[Featured Stock] Access Bio's Self-Diagnostic Home Kit Receives US FDA Emergency Use Authorization...Surges Over 10%

[Asia Economy Reporter Ji-hwan Park] Access Bio is surging on news that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 antigen home test kit.

As of 10:10 a.m. on the 4th, Access Bio is trading at 31,450 KRW, up 10.16% from the previous trading day.

The approved product is the 'CareStartTM COVID-19 Antigen Home Test.' With this approval, Access Bio's product can be purchased anywhere online or offline without a hospital prescription.

This product is characterized by its ability to quickly and easily detect infection within 10 to 15 minutes by collecting a sample from the nasal cavity using a swab. Anyone aged 14 or older can use it alone. Children under 14 can be tested with the help of an adult, making it highly versatile across all age groups.